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Background: Both oxaliplatin/capecitabine-based chemoradiation (OXCAP-RT) and carboplatin-paclitaxel based
radiation (CarPac-RT) are active regimens in oesophageal adenocarcinoma, but no randomised study has compared
their efficacy and toxicity. This randomised phase II “pick a winner” trial will identify the optimum regimen to take
forward to a future phase III trial against neo-adjuvant chemotherapy, the current standard in the UK.
Methods/Design: Patients with resectable adenocarcinoma of the oesophagus or Siewert Type 1–2 gastro-oesophageal
junction (GOJ), ≥T3 and/or ≥ N1 are eligible for the study. Following two cycles of induction OXCAP chemotherapy
(oxaliplatin 130 mg/m2 D1, Cape 625 mg/m2 D1-21, q 3 wk), patients are randomised 1:1 to OXCAP-RT (oxaliplatin
85 mg/m2 Day 1,15,29; capecitabine 625 mg/m2 twice daily on days of RT; RT-45 Gy/25 fractions/5 weeks) or
CarPac-RT (Carboplatin AUC2 and paclitaxel 50 mg/m2 Day 1,8,15,22,29; RT-45 Gy/25 fractions/5 weeks). Restaging
CT/PET-CT is performed 4–6 weeks after CRT, and a two-phase oesophagectomy with two-field lymphadenectomy is
performed six to eight weeks after CRT. The primary end-point is pathological complete response rate (pCR)
at resection and will include central review. Secondary endpoints include: recruitment rate, toxicity, 30-day surgical
morbidity/mortality, resection margin positivity rate and overall survival (median, 3- and 5-yr OS. 76 patients (38/arm)
gives 90% power and one-sided type 1 error of 10% if patients on one novel treatment have a response rate of 35%
while the second treatment has a response rate of 15%. A detailed RT Quality Assurance (RTQA) programme includes
a detailed RT protocol and guidance document, pre-accrual RT workshop, outlining exercise, and central evaluation
of contouring and planning. This trial has been funded by Cancer Research UK (C44694/A14614), sponsored by
Velindre NHS Trust and conducted through the Wales Cancer Trials Unit at Cardiff University on behalf of the
NCRI Upper GI CSG.
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Discussion: Following encouraging results from previous trials, there is an interest in neo-adjuvant chemotherapy and
CRT containing regimens for treatment of oesophageal adenocarcinoma. NEOSCOPE will first establish the efficacy,
safety and feasibility of two different neo-adjuvant CRT regimens prior to a potential phase III trial.
Trial registration: Eudract No: 2012-000640-10. ClinicalTrials.gov: NCT01843829.
Keywords: Oesophageal, Phase II, Neo-adjuvant, Chemotherapy, Chemoradiotherapy, Radiotherapy, Carboplatin,
Paclitaxel, Oxaliplatin, CapecitabineBackground
In the UK, about 7500 patients are diagnosed with oesophageal
cancer each year, of which less than a quarter have resect-
able disease at diagnosis [1]. The most common treatment
strategy in the UK over the past 10 years has been neo-
adjuvant chemotherapy in the form of 2 cycles of cisplatin
and 5-fluorouracil [5FU] prior to surgery. This is based
upon the results of the MRC OE02 trial, which demon-
strated a 6% survival benefit at 5 years for this approach
over surgery alone. The data suggests this improvement
was driven by improved local control rather than reduced
metastatic spread. However, the overall survival is still
poor, just 23% of patients surviving 5 years from treat-
ment [2]. The MRC OE05 trial compared 4 cycles of
neo-adjuvant ECX [epirubicin, cisplatin, capecitabine]
chemotherapy to two cycles of cisplatin/5FU. It recruited
over 800 patients and the final results are awaited.
Oesophageal cancer predominantly presents with locally
advanced or metastatic disease. Even those found to be
suitable for surgery usually present with stage III disease
(at least T3 with lymph node metastases). The oesophagus
lacks a serosal surface and tumours frequently threaten
the circumferential resection margin (CRM). Disease
present at or within 1 mm of the circumferential resection
margin (CRM) (R1 resection) occurs in more than 50% of
stage III cases treated by surgery alone [3,4] and is a poor
prognostic factor. In the OE02 study, the 3-year and the
median survival for patients with R0 and R1 resection
were reported as 42.4% vs. 18% and 2.1 years vs. 1.1 years,
respectively [2]. Like in rectal cancer, neo-adjuvant che-
moradiotherapy [CRT] has the potential to downstage
tumours that threaten CRM and potentially improve
cure rates.
The concept of neo-adjuvant CRT had been previously
rejected in the UK based on the increased mortality re-
ported in previously conducted trials of pre-operative
CRT, and the fact that all but one trial had failed to
show a benefit in overall survival [5]. The landscape of
neo-adjuvant CRT has recently changed with the report-
ing of the CROSS trial [6] which showed no increase in
peri-operative mortality and a near-doubling of median
survival compared to surgery alone. The data for benefit
of pre-operative CRT for squamous cell carcinoma was so
compelling that this is now standard of care. The CROSStrial has regenerated enthusiasm for neoadjuvant CRT tri-
als in the UK and a national oesophageal workshop held
in 2012 identified neo-adjuvant CRT as a key area of fu-
ture research within the UK [7]. This has led to the devel-
opment of the NEOSCOPE trial, which is evaluating CRT
as an addition to pre-operative chemotherapy in adeno-
carcinoma of the oesophagus.
Rationale
Previous trials of pre-operative CRT typically involved
cisplatin-5FU based regimens and reported mortality rates
of around 10% [8]. The CROSS trial, a randomised phase
III study, compared surgery (S) alone to neo-adjuvant
CRT (CRT-S) in 368 patients with operable oesophageal
or gastro-oesophageal junction tumours (of whom ap-
proximately three quarters had adenocarcinoma and one
quarter squamous cell carcinoma histology). The CRT
regimen consisted of weekly carboplatin [AUC 2] and pac-
litaxel [50 mg/m2] concurrent with radiotherapy [41.4 Gy
in 23 fractions]. This trial has shown a superior OS in
favour of the CRT-S arm [OS 49 vs. 24 months, Hazard
Ratio (HR) 0.657, p = 0.003], a pathological complete re-
sponse [pCR] rate of 29%, with no increase in surgical
mortality (4% in both groups) [6]. The R0 resection rates
in the S and CRT-S arms were 69% and 92%, respectively
[p < 0.001]. Of the 178 patients assigned to the CRT-S
arm, 162 (91%) completed protocol treatment of five cy-
cles of chemotherapy and 164 (92%) received full dose
radiotherapy. The study reported a low incidence of Grade
3/4 CRT toxicity [haematological 7%; non-haematological
13%]. Only one death was reported in the CRT arm, prob-
ably due to perforation of the oesophagus accompanied by
major haemorrhage in the absence of thrombocytopenia.
The results of this study, performed in patients with a
similar stage and tumour morphology to those in the UK,
would suggest that where neo-adjuvant CRT is delivered
safely, this leads to a significant improvement in outcome.
Weekly carboplatin/paclitaxel/RT is a novel regimen,
but although promising in its outcome, it had not been
compared against the current standard of care for this dis-
ease, i.e. a neo-adjuvant platinum-5FU based chemother-
apy or CRT.
Oxaliplatin has now been shown to be at least equiva-
lent to cisplatin in advanced upper GI cancers, can be
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favourable toxicity profile compared to cisplatin [9].
Oxaliplatin based CRT has been tested in Phase II trials,
both in the neo-adjuvant and definitive treatment of
oesophageal cancer [10-16]. The PRODIGE5/ACCORD17
trial included patients selected to receive definitive CRT
for oesophageal cancer [17]. In this multi-centre phase 2/3
trial, 267 patients were randomised to either FOLFOX
(n = 134) or cisplatin-5FU (n = 133) in combination with
RT. The median progression-free survival was compar-
able (FOLFOX group 9.7 months, Cisplatin-5FU group
9.4 months, p = 0.64) with no significant differences in
rates of Grade 3/4 toxicity and lower number of toxic
deaths associated with the FOLFOX arm (1 vs 6, p = 0.06).
The authors concluded that FOLFOX-based CRT might
be a more convenient option for patients with localised
oesophageal cancer. In summary, studies of oxaliplatin–
based CRT show promising activity with acceptable toxicity,
may be potentially safer than cisplatin-based regimen, and
therefore justify formal testing in a pre-operative study.
Study objectives
NEOSCOPE is a randomised phase II study which will
test the safety (with regard to post-operative morbidity/
mortality), efficacy (determined by pathological complete
response in the resected specimen, pCR) and feasibility
of recruiting to a randomised multi-centre trial of neo-
adjuvant CRT in the UK.
The randomised phase II design allows us to test two
differing radiosensitiser schedules [carboplatin/paclitaxel
and oxaliplatin/capecitabine] with non-overlapping toxic-
ities. The study is aimed to identify a safe and effective regi-
men that can be taken forward to a future Phase III trial
where neo-adjuvant CRT will be compared with neo-
adjuvant chemotherapy in patients with locally advanced
oesophageal cancer at high risk of R1 disease at surgery.
Additionally, blood and tissue samples will be collected
for translational research and exploratory sub-studies will
investigate whether PET/CT improves the accuracy and
reproducibility of target volume delineation and the role
of Image Guided Radiotherapy (IGRT) in improving the
therapeutic index in oesophageal cancer.
Methods/Design
Study design
NEOSCOPE is a two arm, open, randomised Phase II
trial. It is being run in approximately 19 participating
centres across the UK. Eligible patients will have histo-
logically confirmed adenocarcinoma of the oesophagus
and have been chosen to receive neo-adjuvant CRT by
an accredited multidisciplinary team (MDT) including a
specialist Upper GI surgeon (see Table 1 for detailed
inclusion/exclusion). At randomisation, participants are
assigned to either the OXCAP-RT or CarPac-RT using a1:1 allocation ratio (see Figure 1). Both arms receive induc-
tion OXCAP chemotherapy consisting of 2 cycles of oxali-
platin 130 mg/m2 Day 1, Capecitabine 625 mg/m2 bd Day
1–21, q 3wk). Subsequent to induction chemotherapy, all
patients will receive radiotherapy 45 Gy delivered in 25
daily fractions on weekdays only, by use of conformal
radiotherapy planning. Patients allocated to the OXCAP-
RT arm will receive concomitant oxaliplatin 85 mg/m2 by
intravenous infusion on day 1,15,29 and capecitabine
625 mg/m2 twice daily on days of radiotherapy; patients
on the CarPac-RT arm will receive Carboplatin AUC2 and
paclitaxel 50 mg/m2 by intravenous infusion on days
1,8,15,22,29.
Participant eligibility
Eligible patients will have been diagnosed with adenocar-
cinoma of the oesophagus, or Siewert Type 1 or 2 tumour
of the gastro-oesophageal junction (GOJ) and selected
for treatment with neo-adjuvant CRT by an appropriate
specialised MDT. Such patients may enter the trial if
they meet all inclusion and none of the exclusion entry
criteria (see Table 1).
Staging investigations should include multi-slice/spiral
CT scan of thorax and abdomen (neck and pelvis op-
tional) with IV and oral contrast/water, maximum slice
width 5 mm, endoscopic ultrasound (EUS), PET/CT scan
(recommended but not essential) and laparoscopy (where
clinically indicated – usually for lower third and GOJ tu-
mours). All staging investigations should be ideally com-
pleted within four weeks prior to randomisation. However
if this is not possible, the last staging investigation, which
may include CT, EUS, PET/CT, or laparoscopy, should
normally be performed within four weeks prior to ran-
domisation. Cardiac and respiratory assessment (FEV1
using spirometer, cardiac ejection fraction using echocar-
diogram or MUGA and ECG) should also be performed
within four weeks prior to randomisation. Within one
week prior to randomisation the following screening as-
sessments should be performed: a history and physical
examination (to include height, weight and WHO per-
formance status); full blood count; serum renal, liver and
bone profile (including serum magnesium); glomerular fil-
tration rate; electrocardiogram; and pregnancy test in fe-
males of child bearing age.
Sample size considerations
The sample size calculations are based on the maximum
of two binomial random variables and follow the ideas
of Dunnett [18]. The primary outcome of the study is
rate of pathological complete response in the resection
specimen. A response rate of 15% would not be suffi-
ciently large to warrant further investigation, while a re-
sponse rate of 35% is considered worthwhile. Patients
will be randomised 1:1 to each of the two treatment
Table 1 Inclusion and exclusion criteria for the
NEOSCOPE trial
Inclusion criteria
Patients meeting any of the following criteria may be included
in the trial:
1. Histologically confirmed operable oesophageal cancer
[adenocarcinoma]
2. T3/T4 with any N stage OR N1 with any T stage (TNM6). This will
be equivalent to T3/T4a with any N stage OR N1-3 with any
T stage (TNM7). T4a tumours should;
a. involve only the diaphragm or crura, or
b. invade only the mediastinal pleura, or
c. breach the gastric serosa (TNM 7).
Tumours with nodal disease (N1-3) affecting the origin of the
left gastric and splenic artery with the coeliac axis
(formerly staged as M1a in TNM 6) can be included.
3. Maximum disease (T + N) length 8 cm staged with EUS and
CT/PET with maximum extent of primary disease below the
gastro-oesophageal junction being 3 cm.
4. WHO performance status 0–1 and patient fit to be treated
with combined modality therapy (chemotherapy and
radiotherapy prior to surgery).
5. Adequate respiratory and cardiac function: FEV1 > 1.5 litres
and cardiac ejection fraction ≥50% on echocardiography or
MUGA. These assessments should normally be performed within
4 weeks prior to randomisation. CPEX testing is allowable but
must not replace the above investigations. Patients who have
had their assessments done over 4 weeks prior to randomisation
or have had borderline results may still be eligible provided that
they have approval from the CI through the NeoSCOPE trial team.
6. Adequate haematological, renal, and hepatic function:
a. Liver function tests ≤1.5 × ULN
b. White blood cell count ≥ 3 × 109/l; platelets ≥ 100 × 109/l.
c. Glomerular filtration rate (GFR) >50 ml/minute calculated
or measured.
The above assessments should normally be performed within
1 week prior to randomisation. Patients who have had their
assessments done over 1 week prior to randomisation or have
had borderline results may still be eligible provided that they
have approval from the CI through the trial team.
7. The patient has provided written informed consent.
8. The patient is at least 18 years old.
Exclusion criteria
If any of the following criteria apply, patients cannot be
included in the trial:
1. Oesophageal cancer with histology other than adenocarcinoma
2. Uncontrolled angina pectoris, myocardial infarction within 6 months,
heart failure, clinically significant uncontrolled cardiac arrhythmias,
or any patient with a clinically significant abnormal ECG.
3. Patients with any previous treatment for oesophageal carcinoma.
4. Siewert type 3 oesophago-gastric tumours.
5. Lower limit of the endoscopically visible primary tumour
should not involve stomach for more than 3 cm distal to the
gastro-oesophageal junction.
6. T4 tumours invading contiguous structures other than
diaphragm, crura or mediastinal pleura.
Table 1 Inclusion and exclusion criteria for the
NEOSCOPE trial (Continued)
7. Patients with disease in any of the following areas on the
CT scan, EUS or other staging investigation:
a. Evidence of metastases in liver, lung, bone or other
distant metastases.
b. Abdominal para aortic lymphadenopathy >1 cm diameter
on CT or >6 mm diameter on EUS.
c. Invasion of tracheo-bronchial tree, aorta, pericardium or lung.
8. Lymphadenopathy encasing the coeliac axis (as described above,
patients with single nodes lying anterior to the origin of the
splenic artery and anterior to the origin of the coeliac axis are
not excluded).
9. Any patient with a single significant medical condition which
is thought likely to compromise his or her ability to tolerate any
of the above therapies.
10. Specific contra-indications to surgery, chemotherapeutic agents
(including known allergies to chemotherapy) or radiotherapy.
11. Patients with another previous or current malignant disease which
in the judgement of the treating investigator is likely to interfere
with treatment or the assessment of response.
12. Pregnant or lactating women and fertile women who will not
be using contraception during the trial.
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patients/arm). This design is based on a one-sided type I
error of 10% and a power of 90% of achieving significance if
patients on one novel treatment have a response rate of 35%
while the second treatment has a response rate of 15%. This
specification ensures that a power greater 90% is achieved
if both treatments have a worthwhile effect of 35%. The
study will seek to recruit a maximum total of 85 patients
to account for a 10% drop-out rate before resection.
Method of randomisation
Wales Cancer Trials Unit will randomise patients cen-
trally using the method of minimisation with a random
element. This will ensure balanced treatment allocation
by a number of clinically important stratification factors.
Randomisation will have an allocation ratio of 1:1.
Outcome measures
Primary outcome measure
Efficacy: Pathological complete response rate (pCR) to be
assessed in the resected specimen following neo-adjuvant
treatment using standardised work up of the resection
specimen in the pathology department and standardised
histological criteria for tumour regression grading includ-
ing central pathology review of all specimens.
Secondary outcome measures
Feasibility: of recruiting oesophageal cancer patients to a
pre-operative CRT trial in the UK as determined by re-
cruitment within 18 months.
Figure 1 Trial schema.
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morbidity/mortality, toxicities (CTCAE version 4.03) during
treatment and late treatment toxicity at 6 and 12 months.
Efficacy: CRM positivity (as defined by the Royal College
of Pathologist’s guidelines), resection rate and overall sur-
vival (median, 3 and 5 year).Data collection
Participants will be seen at hospital at randomisation,
the end of each treatment cycle, 4 weeks post CRT,
30 days post-surgery and then at month 6 and 12 post-
surgery. Research staff at the hospitals will be expected
to complete trial CRFs which record evidence of primary
and secondary outcome measures. Patients will be
flagged with the Health and Social Care Information
Centre for longer term follow up of survival. Data on
quality of life and health economics is not being col-
lected in this Phase II study.Statistical analysis
All analyses will be on an intention-to-treat basis, i.e. all
patients randomised will be included, and all patients will
be analysed according to their allocated group whatever
treatment they received. Statistical analysis will include:
 Descriptive statistics of the patient characteristics
within each treatment group
 A CONSORT flow diagram of enrolment,
intervention allocation, and follow-up
 Tables of toxicities at each timepoint (baseline, end
of CRT (including all those during treatment),
30 days post-surgery, and then during later follow up.
 Treatment compliance during each cycle (in terms
of proportions of patients with delay/reduction to
CRT) within each treatment group. An exploration
of predictors of poor compliance will be performed.
When 10 patients have completed treatment, i.e. 5 pa-
tients in either arm, a safety review will be performed.
Full SAE and toxicity by arm will be presented to the
Independent Data Monitoring Committee (IDMC) for a
recommendation as to whether or not to continue recruit-
ment. Additionally, upon any event of 30-day postopera-
tive mortality, the IDMC and Trial Management Group
(TMG) will be notified to discuss whether or not the trial
should continue. The TMG will consider making a change
to the radiotherapy protocol if necessary.
A full statistical analysis plan will be defined before
the first interim analysis of the trial. Upon completion of
recruitment and follow up, the pCR rates and post- op-
erative mortality rates will be calculated by arm. The fol-
lowing rules will be used to decide whether or not there
is sufficient evidence to warrant a future Phase III trial: If fewer than 10 patients achieve a pCR to either
treatment, no treatment is taken forward to a Phase
III trial.
 If 10 or more patients achieve a pCR to treatment A
but fewer than 10 patients achieve a pCR to
treatment B, treatment A is taken forward to a
Phase III trial.
 If 10 or more patients achieve a pCR to treatment B,
but fewer than 10 patients achieve a pCR to treatment
A, treatment B is taken forward to a Phase III trial.
 If both treatments have 10 or more patients achieve
a pCR, the treatment with higher response rate is
taken forward to a Phase III study provided the post
operative mortality is less than 5% in both arms. If
post operative mortality is > 5% for one of the
treatments while the mortality is below 5% for the
other, the treatment with the lower post-operative
mortality is taken forward.
 If both arms show high pCR and similar mortality
then toxicities will be used to help decide which arm
to take forward to a future Phase III.
Radiotherapy quality assurance
The aim of the RTQA programme is to ensure compli-
ance with the protocol and consists of both pre-accrual
and on-trial (individual case) components. A detailed
radiotherapy protocol and quality assurance procedure
(Radiotherapy Trials Quality Assurance (RTTQA)) has
been incorporated into this trial in collaboration with
the NCRI RTTQA group at Velindre Hospital. This
can be accessed at http://www.rttrialsqa.org.uk/rttqa/?q =
neoscope. Protocol development was an iterative process
over several months with incorporation of comments from
several upper GI oncologists. The definition of target vol-
umes and margins for NEOSCOPE has been informed by
three main sources: (i) the CROSS trial radiotherapy proto-
col (ii) European Organization for the Research and Treat-
ment of Cancer (EORTC) recommendations for the use of
naCRT in adenocarcinomas of the gastro-oesophageal
junction and the stomach [19] and (iii) the radiotherapy
protocol of Art Deco (A Randomised Trial of Dose
Escalation in definitive chemoradiotherapy for patients with
Oesophageal cancer), a definitive CRT trial run by the
CROSS group (M. Hulshof, personal communication).
Pre-accrual RTTQA
Prior to trial participation centres were required to satis-
factorily complete a pre-accrual benchmark outlining and
planning case. Investigators were asked to outline a middle
and lower 1/3 oesophageal case and to plan a pre-outlined
lower 1/3 case, both according to the protocol. All rele-
vant clinical information and diagnostic imaging were pro-
vided, facilitated by the UK RTTQA website (http://www.
rttrialsqa.org.uk/). A consensus reference volume was used
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RTTQA team and detailed feedback was provided, in-
cluding screenshots of their volumes overlying the refer-
ence volume. Criteria were developed for pass, minor and
major deviations. Centres were asked to resubmit failed
cases until satisfactory. Planning case and RT process was
also QAed and fed back on, in the same manner, with ad-
vice suggested for improvement where necessary.Real time RTTQA
Individual case review is carried out prospectively for
the 1st case from each centre and for the first 20 cases,
repeating the process if there was an issue, until there is
a satisfactory submission. We have paid particular atten-
tion to areas of variation identified in the pre-accrual
cases. We will feed back to centres within 3 working days.
For all remaining cases we use ‘timely retrospective review’,
where outlines and plans are reviewed within 2 weeks of
the start of radiotherapy.Translational research
The clinical trial includes tissue sample collection for fu-
ture translational research and the development/valid-
ation of biomarkers. Trial participants will be asked for
additional optional consent to participate in this aspect
of the study. The biobank for this clinical trial will con-
sist of pre-treatment diagnostic biopsy tissue, including
one or more formalin-fixed, paraffin-embedded blocks of
tumour and one block of normal mucosa, and 2 × 10 ml
EDTA blood samples to be taken within 14 days before
the first day of cycle 1 of chemotherapy. All samples will
be stored at the Wales Cancer Bank for future transla-
tional research.Regulatory approval, sponsorship and current status
NEOSCOPE has been ethically approved by the Research
Ethics Committee for Wales and has approval from the
Medicines and Health Care Product Regulatory Agency to
be conducted in the UK. The Wales Cancer Trials Unit, a
Cancer Research UK core funded and UKCRC accredited
Clinical Trials Unit, is coordinating the trial. Velindre
NHS Trust is the sponsor for the trial. A Trial Steering
Committee and an Independent Data Monitoring Committee
has been set up to monitor the progress and safety of the
study. The NEOSCOPE Trial Management Group, in-
cluding clinicians, clinical trial unit staff, patient repre-
sentatives, nursing and pharmacy representatives, carry
out the day-to-day running of the trial. The full trial
protocol can be accessed at http://www.rttrialsqa.org.uk/
rttqa/?q=neoscope.
NEOSCOPE is registered with Eudract No: 2012-000640-
10 and Clinical trial information: NCT01843829.The study opened to recruitment in September 2013,
is open in 19 centres across UK and as of 8 September
2014 had recruited 43 patients.
Discussion
This Cancer Research UK funded trial aims to define a safe
and effective pre-operative CRT regimen in oesophageal
adenocarcinoma to take forward to a phase III trial. The
OE05 study, a randomised phase III trial, which recruited
over 800 patients and compared 2 cycles of cisplatin-5FU
chemotherapy to 4 cycles of ECX (epirubicin, capecitabine,
cisplatin), is due to report later this year and is expected
to define the optimal neo-adjuvant chemotherapy regi-
men. It is proposed that the best arm of NEOSCOPE will
be taken forward to a phase III trial against the best arm of
OE05. This study also builds on the high quality RTTQA
programme which was built around the SCOPE trial [20]
and aims to standardise the delivery of pre-operative radio-
therapy across the UK.
The use of neo-adjuvant CRT in oesophageal cancer
has been tested in a number of studies, which have been
heterogeneous in design, size and treatment regimen tested.
Nevertheless, a meta-analysis of randomised trials has
shown that this approach increases R0 resection rates, re-
duces loco-regional recurrence and improves survival
compared with surgery alone [8]. There has been only one
randomised phase III trial comparing pre-operative chemo-
therapy with pre-operative CRT. This study by Stahl et al.
aimed to recruit 354 patients to detect a 10% improvement
in 3-year overall survival [OS] in favour of CRT [from 25%
to 35%] but closed early due to poor recruitment (126 pa-
tients recruited over 5 years). Nonetheless, it showed a
non-significant trend towards improved 3-year survival in
favour of CRT [47.4% v 27.7%, p = 0.07] [21].
Through better selection of patients, improved peri-
operative care and centralisation of upper gastro-intestinal
surgical services, there has been a significant reduction in
post-operative mortality. In the MRC OE02 trial, the post-
operative mortality was 10% in patients receiving either
neo-adjuvant chemotherapy or surgery alone [22]. In the
3rd Annual Report of the UK National Oesophago-Gastric
Cancer Audit (26th March 2012), the post-operative mor-
tality was 3.8% and many large surgical centres now have
rates of in-hospital mortality of < 3% [23]. Neo-adjuvant
CRT has been historically associated with higher post-
operative mortality. In the Urschel meta-analysis, there
was a non-significant increase in peri-operative mortality
[1.72 (0.96, 3.07; p = 0.07)] and increase in all-treatment
mortality that was of borderline significance [1.63 (0.99,
2.68; p = 0.053)] [8]. In the Stahl trial of neo-adjuvant CRT
vs. neo-adjuvant CT, there was a trend towards increased
post-operative mortality [5 of 49 (10.2%) vs. 2 of 52 (3.8%,
p = 0.26] [21]. Although only recently reported, this study
was designed in the 1990s and opened to recruitment in
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rapy was recommended but not mandated as part of this
trial. This, together with the lack of pre/on-trial RT quality
assurance, may have contributed to increased post-operative
morbidity and mortality. Contrary to this, the CROSS trial
found no significant increase in peri-operative mortality,
which probably reflects the use of patient selection and
improvement in surgical care and radiotherapy delivery
over time.
In recent years, a great deal of work has been done to raise
the standards of conformal radiotherapy for oesophageal
cancer in the UK. Through a detailed protocol and quality
assurance procedures, including test cases and on trial re-
view of plans, the SCOPE 1 trial, a randomised trial of de-
finitive CRT with cisplatin and capecitabine with/without
Cetuximab, recruited greater than 250 patients from 44
radiotherapy centres and demonstrated that the UK can
perform high quality, multi-centre RT based studies safely
[24]. This trial has allowed UK investigators to gain sig-
nificant experience in delivering quality assured CRT and
this provides an ideal platform on which to build a neo-
adjuvant study, and to investigate precise methods of
tumour localisation such as CT/PET and image-guided
radiotherapy [IGRT], all of which should allow safer and
more accurate delivery of RT, reduction of radiation dam-
age to organs at risk and ultimately reduce post-operative
morbidity and mortality.
The current UK standard practice has been largely in-
fluenced by the results of the MRC OE02 trial and until
recently, clinicians had been actively recruiting to the
MRC OE05 trial. Concerns about increased post-operative
mortality/morbidity from neo-adjuvant CRT as well as
participation in the MRC OE05 trial had discouraged rou-
tine use of neo-adjuvant CRT. However, the MRC OE05
trial has now closed to recruitment, the outcome with
neo-adjuvant chemotherapy alone remains poor and the
CROSS trial demonstrated that neo-adjuvant CRT can be
given with acceptable morbidity, and when done so, is as-
sociated with a significant survival advantage. The UK has
now seen the development of a high quality upper GI RT
Quality Assurance programme through the SCOPE 1 trial.
This, along with better patient selection through new im-
aging techniques like PET-CT and EUS, and improvement
in peri-operative care through centralisation of surgical
services, is expected to lead to better outcome than re-
ported in previous neo-adjuvant CRT trials.
Based on the above, there is a growing clinical consensus
that the two strategies of neo-adjuvant chemotherapy and
CRT containing regimens should be compared head-to-
head in a prospective randomised controlled trial in
oesophageal adenocarcinoma, particularly focussing on
those patients who are at high risk of R1 surgical resection.
NEOSCOPE will first establish the efficacy, safety and
feasibility of two different neo-adjuvant CRT regimens.Competing interests
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